Hyperfine (HYPR) AI Stock Analysis

• Market Cap: $106.08M
• Dividend Yield: N/A
• Average Volume (3M): 337.81K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.46
• Revenue Growth: -9.59%
• EPS Growth: 8.78%
• Country: US
• Employees: 111
• Sector: Healthcare
• Sector Strength: 51
• Industry: Medical - Devices
• EPS (TTM): -0.12
• Shares Outstanding: 63,525,715
• 10 Day Avg. Volume: 251,464
• 30 Day Avg. Volume: 337,812
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.29
• Enterprise Value/Revenue: 2.86
• Enterprise Value/Gross Profit: 6.24
• Enterprise Value/Ebitda: -0.74
• 1Y Price Target: $1.42
• Price Target Upside: 0.00%
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 57 Neutral
• Price Target: $1.50 ▲(5.63% Upside)

Hyperfine's overall stock score is driven by strong technical momentum and positive earnings call insights, indicating potential growth and strategic advancements. However, significant profitability challenges and valuation concerns due to ongoing losses weigh down the score.

Positive Factors

Revenue Growth

The sequential revenue growth of 26% indicates strong market demand and successful sales strategy, contributing to long-term business expansion.

FDA Clearances

FDA clearances for new technologies enhance product credibility and marketability, potentially increasing adoption and driving future growth.

International Expansion

Expanding into international markets diversifies revenue streams and reduces dependency on domestic sales, supporting long-term growth.

Negative Factors

Net Loss

Ongoing net losses highlight profitability challenges, which may strain cash reserves and hinder sustainable growth if not addressed.

Negative Cash Flow

Persistent negative cash flow indicates potential liquidity issues, limiting the company's ability to invest in growth opportunities.

Chairperson Resignation

Leadership changes can disrupt strategic continuity and impact investor confidence, potentially affecting long-term strategic execution.

Hyperfine Business Overview & Revenue Model

Company Description

Hyperfine, Inc. provides imaging, monitoring, and magnetic resonance imaging products. It offers Swoop Portable MR imaging system to address an unmet need in point-of-care medical imaging through a combination of hardware and software services. The company was incorporated in 2014 and is based in Guilford, Connecticut.

How the Company Makes Money

Hyperfine generates revenue primarily through the sale and leasing of its Swoop portable MRI systems. The company also earns income from service contracts, offering maintenance and technical support for their equipment. Additional revenue streams may include training services for medical staff and software updates for the MRI systems. Significant partnerships with healthcare providers and research institutions further enhance its market reach and adoption of its innovative MRI technology.

Hyperfine Financial Statement Overview

Summary

Hyperfine shows strong revenue growth and a solid equity position with no debt. However, persistent net losses and negative cash flows highlight significant profitability challenges. The high equity ratio and lack of debt provide stability, but the negative ROE and cash flow issues indicate a need for improved operational efficiency.

Income Statement

Hyperfine's income statement shows significant revenue growth over the years, with the latest revenue of $12.89 million compared to $0.29 million in 2020. However, the company continues to operate at a loss, with a net loss of $40.72 million for 2024. The gross profit margin has improved to 45.7% in 2024 from a negative margin in earlier years, but net profit margins remain substantially negative. The EBIT and EBITDA margins are also deeply negative, indicating ongoing operational challenges. The revenue growth is a positive sign, but the persistent losses are a major concern.

Balance Sheet

The balance sheet of Hyperfine shows a relatively strong equity position with stockholders' equity at $49.04 million by the end of 2024. The company has no debt, resulting in a debt-to-equity ratio of 0, which is a positive aspect. However, the return on equity is negative due to significant net losses. The equity ratio stands at 83.2%, indicating a strong capital structure. The absence of debt and a high equity ratio are strengths, yet the negative ROE reflects profitability challenges.

Cash Flow

Hyperfine's cash flow statement reveals negative free cash flow, with a free cash flow of -$39.15 million in 2024. Operating cash flow exceeds net income, suggesting decent cash conversion efficiency, but both metrics are negative. The company has been investing less over time, which may impact future growth prospects. While the company has managed to finance operations without debt, the continuous negative cash flows pose a risk to long-term sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	10.80M	12.89M	11.03M	6.81M	1.50M	294.00K
Gross Profit	4.95M	5.89M	4.76M	907.00K	-1.17M	-477.00K
EBITDA	-41.50M	-42.22M	-47.06M	-72.86M	-64.14M	-23.20M
Net Income	-39.36M	-40.72M	-44.24M	-73.16M	-64.83M	-23.36M
Balance Sheet
Total Assets	45.23M	58.90M	94.20M	134.05M	202.47M	71.53M
Cash, Cash Equivalents and Short-Term Investments	25.42M	37.65M	75.18M	117.47M	188.50M	62.68M
Total Debt	250.00K	269.00K	185.00K	0.00	0.00	178.00K
Total Liabilities	10.11M	9.86M	9.80M	10.33M	16.25M	132.58M
Stockholders Equity	35.13M	49.04M	84.40M	123.72M	186.23M	-61.05M
Cash Flow
Free Cash Flow	-35.19M	-39.15M	-42.61M	-72.92M	-49.89M	-23.09M
Operating Cash Flow	-34.03M	-38.77M	-41.81M	-72.34M	-47.18M	-21.52M
Investing Cash Flow	-1.16M	-383.00K	-804.00K	-585.00K	-2.71M	-1.57M
Financing Cash Flow	6.96M	1.02M	174.00K	7.00K	176.77M	60.94M

Hyperfine Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.42
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYPR, the sentiment is Positive. The current price of 1.42 is above the 20-day moving average (MA) of 1.26, above the 50-day MA of 1.12, and above the 200-day MA of 0.94, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 66.52 is Neutral, neither overbought nor oversold. The STOCH value of 90.44 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HYPR.

Hyperfine Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FONR	77 Outperform	$99.07M	12.85	5.00%	―	0.29%	-22.13%
HYPR	57 Neutral	$106.08M	―	-77.26%	―	-9.59%	8.78%
Sector *	51 Neutral	$8.02B	-0.31	-43.38%	2.24%	22.31%	-2.14%
MODD	―	$38.70M	―	-215.41%	―	―	―
VVOS	48 Neutral	$27.32M	―	-262.03%	―	2.65%	70.21%
ICCM	46 Neutral	$68.21M	―	-230.80%	―	-16.46%	4.14%
RBOT	39 Underperform	$34.64M	―	-125.63%	―	―	6.48%

Hyperfine Corporate Events

Hyperfine Regains Nasdaq Compliance with Bid Price

On April 30, 2025, Hyperfine, Inc. was notified by Nasdaq that its Class A common stock had fallen below the minimum bid price requirement of $1.00 per share for 30 consecutive business days. However, by August 6, 2025, Hyperfine regained compliance with the Nasdaq’s bid price requirement, thus resolving the issue.